|
|
 |
|
Viewing report
|
|
|
|
Investing in Stem Cell Companies in 2010 and Beyond
BioPolaris, Feb 2010, Pages: 114
Stem cell market is on the brink of explosion. The first approval of stem cell-based therapeutic product will push the whole market forward not only financially but also acceptance of stem cells as the mode of therapy and eventually prevention of a variety of diseases by general public will increase.
And this will happen relatively soon. Presently there are over 160 stem cell-based therapeutic products undergoing development, with 27 of them in the phase II or III clinical trials.
In the near future, stem cell therapeutic products will affect the major health care segments, including cardiovascular, stroke and diabetes. Anticipated reduce in gross domestic product (GDP) between 1 and 5% in low and middle income countries will be caused by heart diseases, stroke and diabetes, as many people will die prematurely. For example, it is estimated that between 2006-2015, China will lose at least $558 billion of its national income due to the combination of heart disease, stroke and diabetes. The most recent data from the American Heart Association’s Heart Disease and Stroke Statistics 2008 update reveals that projected cost related to heart diseases in 2009 will grow to more than $304.6 billion, including health care services, medications, and lost productivity. Direct medical cost of treating patients with diabetes is expecting to triple in next 25 years, going from $113 billion today to $336 billion per year in the USA alone. Stem cell market consists of three sectors: stem cell-based therapeutic sector, stem cell banking sector and stem cell-based products and services providers sector. Each sector has its own characteristics, risk factors and different potential for growth.
The Investing in Stem Cell Companies in 2010 and Beyond report features characteristics of 51 public companies that are playing role in stem cells market. The companies are divided in four groups: stem cell-based therapeutic products research and development companies, stem cell services and product provider companies, stem cell banking companies, and finally large pharmaceutical and laboratory products companies involved in stem cell business, such as sales of stem cell-based products or research and development of stem cell-based therapies. Each company’s profile summarizes its business with R & D pipeline and type of cells used for the treatment, if available, stock information with one year stock chart, valuation and financial data, including profitability and management effectiveness, income statement and balance sheet and cash flow. The cross-section of all available financial data for each company was executed on January 15, 2010.
Customers who bought this item also bought
Cell and Stem Cell Therapies for Diabetes
Personalized Medicine - Scientific and Commercial Aspects
Global Stem Cell and Advanced Technologies Market
Stem Cell Therapy for Stroke
Regenerative Medicine Markets
The Central Nervous Systems Market 2010 Report
Stem Cell Therapy for Cardiac Diseases
Stem Cell Therapy for Spinal Cord Injury
Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market
Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition
|
|
|
|
